Scynexis
$0.89
39
-$0.03-3.12% Today
Statistics
Day High
0.91
Day Low
0.83
52W High
1.31
52W Low
0.57
Volume
633,695
Avg. Volume
577,339
Mkt Cap
37.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-0.126667
Actual EPS
N/A
Financials
-568.29%Profit Margin
Unprofitable7.49MRevenue
-42.58MNet Income
Analyst Ratings
$3.00Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow SCYX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Gilead Sciences
GILD
Mkt Cap148.78B
Astrazeneca
AZN
Mkt Cap256.58B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Abbvie
ABBV
Mkt Cap385.18B
Novartis
NVS
Mkt Cap237.61B
AMGEN
AMGN
Mkt Cap160.66B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Sanofi
SNY
Mkt Cap124.45B
About
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Show more...
CEO
Dr. David Gonzalez Angulo M.D.
Employees
28
Country
US
ISIN
US8112922005
Listings
0 Comments
Share your thoughts
FAQ
What is Scynexis stock price today?▼
The current price of SCYX is $0.89 USD — it has decreased by -3.12% in the past 24 hours. Watch Scynexis stock price performance more closely on the chart.
What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scynexis stocks are traded under the ticker SCYX.
Is Scynexis stock price growing?▼
SCYX stock has risen by +0.85% compared to the previous week, the month change is a +18.44% rise, over the last year Scynexis has showed a -5.74% decrease.
What is Scynexis market cap?▼
Today Scynexis has the market capitalization of 37.28M
When is the next Scynexis earnings date?▼
Scynexis is going to release the next earnings report on May 07, 2026.
What were Scynexis earnings last quarter?▼
SCYX earnings for the last quarter are 0.25 USD per share, whereas the estimation was 0.13 USD resulting in a +97.37% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scynexis revenue for the last year?▼
Scynexis revenue for the last year amounts to 7.49M USD.
What is Scynexis net income for the last year?▼
SCYX net income for the last year is -42.58M USD.
How many employees does Scynexis have?▼
As of April 01, 2026, the company has 28 employees.
In which sector is Scynexis located?▼
Scynexis operates in the Health Care sector.
When did Scynexis complete a stock split?▼
The last stock split for Scynexis was on July 17, 2020 with a ratio of 1:10.
Where is Scynexis headquartered?▼
Scynexis is headquartered in Jersey City, US.